These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 17306255

  • 1. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
    El-On J, Bazarsky E, Sneir R.
    Exp Parasitol; 2007 Jun; 116(2):156-62. PubMed ID: 17306255
    [Abstract] [Full Text] [Related]

  • 2. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
    el-On J, Sulitzeanu A, Schnur LF.
    Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981
    [Abstract] [Full Text] [Related]

  • 3. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    Grogl M, Schuster BG, Ellis WY, Berman JD.
    J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
    [Abstract] [Full Text] [Related]

  • 4. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
    Schwartz J, Moreno E, Calvo A, Blanco L, Fernández-Rubio C, Sanmartín C, Nguewa P, Irache JM, Larrea E, Espuelas S.
    J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
    [Abstract] [Full Text] [Related]

  • 5. The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
    Livneh A, Youngster I, El-On Y, Berkovitch M, Abu-Kishk I.
    Acta Parasitol; 2015 Jun; 60(2):345-9. PubMed ID: 26204005
    [Abstract] [Full Text] [Related]

  • 6. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N, Fazly Bazzaz BS, Khamesipour A, Jaafari MR.
    Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
    [Abstract] [Full Text] [Related]

  • 7. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin.
    Carter KC, Alexander J, Baillie AJ.
    Ann Trop Med Parasitol; 1989 Jun; 83(3):233-9. PubMed ID: 2604461
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU, Lemke KR.
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [Abstract] [Full Text] [Related]

  • 12. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study.
    el-On J, Halevy S, Grunwald MH, Weinrauch L.
    J Am Acad Dermatol; 1992 Aug; 27(2 Pt 1):227-31. PubMed ID: 1430361
    [Abstract] [Full Text] [Related]

  • 13. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
    Arana BA, Mendoza CE, Rizzo NR, Kroeger A.
    Am J Trop Med Hyg; 2001 Nov; 65(5):466-70. PubMed ID: 11716099
    [Abstract] [Full Text] [Related]

  • 14. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride.
    el-On J, Weinrauch L, Livshin R, Even-Paz Z, Jacobs GP.
    Br Med J (Clin Res Ed); 1985 Sep 14; 291(6497):704-5. PubMed ID: 3929905
    [No Abstract] [Full Text] [Related]

  • 15. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
    El-On J, Jacobs GP, Witztum E, Greenblatt CL.
    Antimicrob Agents Chemother; 1984 Nov 14; 26(5):745-51. PubMed ID: 6517557
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.
    Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL.
    Antimicrob Agents Chemother; 2017 Aug 14; 61(8):. PubMed ID: 28607026
    [Abstract] [Full Text] [Related]

  • 17. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 14; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 18. Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.
    Khalili G, Dobakhti F, Mahmoudzadeh-Niknam H, Khaze V, Partovi F.
    Iran J Immunol; 2011 Mar 14; 8(1):45-51. PubMed ID: 21427495
    [Abstract] [Full Text] [Related]

  • 19. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan 14; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.